Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)

Central Hospital, Nancy, France

Status: Completed

Conditions: Intra Abdominal Infections; Candidiasis, Invasive; Critically Ill; Peritoneal Candidiasis

Treatments: Diagnostic Test: 1.3 BETA D GLUCAN

Study type: Observational

Funder types: Other

Identifiers

NCT03997929

2019PI074

Details and patient eligibility

About

New rapid diagnostic strategies are warranted in intra-abdominal candidiasis (IAC). A previous retrospective study showed that one measure, the day of the surgery, of peritoneal 1.3-Beta-D-Glucan ≤ 310pg/ml could rule out an IAC. This strategy was independent of the patient underlying conditions and Candida risk factors. This study aimed to confirm these results with a multicenter prospective study

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• critically ill adult (> 18 yrs old) admitted to ICU for intra-abdominal infection requiring surgery and possible intra abdominal candidiasis

Exclusion criteria

• declinate to participate,
• expected death within the first 24 hours

Trial design

200 participants in 2 patient groups

CASE (intra abdominal candidiasis)

Description:

Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection

Treatment:

Diagnostic Test: 1.3 BETA D GLUCAN

CONTROL (bacterial intra abdominal infection)

Description:

Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)

Treatment:

Diagnostic Test: 1.3 BETA D GLUCAN